Record of Telephone Conversation, December 23, 2011 - Flucelvax
Submission Type: BLA Submission ID: 125408/0 Office: OVRR
Influenza Vaccine (MDCK Cells)
Novartis Vaccines and Diagnostics GmbH
Telecon Date/Time: 23-Dec-2011 01:09 PM Initiated by FDA? Yes
Author: TIMOTHY FRITZ
Clarification for SRID test results submission.
FDA Participants: Timothy Fritz
Non-FDA Participants: Ingeborg Cebulla, John Barry
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
From: Fritz, Timothy
Sent: Friday, December 23, 2011 1:09 PM
Subject: CBER clarification for SRID testing
Dear Dr. Cebulla-
Novartis and CBER held a teleconference on November 17, 2011, to discuss SRID testing of Novartis' MDCK cell-based influenza antigens. CBER received a summary of the discussion from Novartis via e-mail on November 18, 2011. In this e-mail, Novartis indicated that CBER recommended that Novartis submit an amendment to the Optaflu BLA "if cell based reagents need to be developed and used."
CBER wishes to clarify that it also recommends that Novartis submit assay results of SRID experiments assessing the suitability of egg-based influenza reagents in the event that those results support the use of egg-based reagents for measuring the potency of the MDCK cell-produced influenza antigens. CBER recommends that these results be submitted as an amendment to the Optaflu BLA (STN 125408). CBER would appreciate an estimate of when Novartis expects to complete the suitability study.
If you have any questions, please contact the Regulatory Project Managers, Dr. Brenda Baldwin or Dr. Timothy Fritz, at 301-796-2640 or via e-mail.
Timothy A. Fritz, Ph.D.
1451 Rockville Pike
Rockville, MD 20852
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify the sender immediately by e-mail or phone.